
Global Exosome Technologies Market to 2024: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players - ResearchAndMarkets.com
The "Exosome
Technologies: Recent Surge in R&D with Capricor, Codiak and Evox
Therapeutics among Key Players" report has been added to ResearchAndMarkets.com's
offering.
This explores the application of Exosome technologies within the pharmaceutical and healthcare industries.
Exosomes are small cell-derived vesicles that are abundant in bodily
fluids, including blood, urine, cerebrospinal fluid (CSF) as well as in
in vitro cell culture. These vesicles are being used in a variety of
therapeutic applications, including as therapeutic biomarkers, drug
delivery systems and therapies in their own right.
Exosome
can be engineered to incorporate targeting ligands, allowing them to
deliver cargo selectively to cells. Their small size allows them to
penetrate the blood-brain barrier (BBB) for the delivery of central
nervous system (CNS) therapies, whereas in cancer they can accumulate
within the tumor via enhanced permeability and retention effects.
Research within this area remains in the nascent stages, though several
clinical studies have been registered within the field.
Although
research within the exosome field is in the early stages, the area
boasts a broad and diverse pipeline consisting of 22 active products.
The majority of these products are within the Preclinical stage of
development, and are indicated for the treatment of cancer. Other
therapeutic areas strongly represented in this pipeline include the CNS
and cardiovascular therapy areas. The clinical trials landscape for
exosome therapies is similarly diverse. Since 2006, a total of 124
clinical trials have taken place.
As a result, interest and
investment within the field of exosome therapies have been increasing
steadily over the past 10 years. Currently there is only one product
approved for use on the market, the Exodx Prostate Intelliscore
diagnostic test for prostate cancer, developed and marketed by Exosome
Diagnostics.
There are a range of companies within the
pipeline landscape, most of which have only become established within
the past few years. One of the leading companies in this sector is
Capricor Therapeutics. The company is forecast to make a profit on the
market with a net revenue of $333 million forecast for 2024 attributable
to the anticipated successful development of its key product CAP-1002.
This
report provides detailed information on the various healthcare
applications of exosomes, and assesses the pipeline, clinical trial and
company landscapes.
Scope
- What are the features of the exosome lifecycle?
- How are therapeutic exosomes prepared?
- How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?
- Which companies are investing in exosome technologies?
- How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?
Key Topics Covered:
1 Table of Contents
2 Exosomes in
Healthcare
2.1 Overview of Exosomes
2.2 Drug Delivery
Systems
2.3 The Exosome Lifecycle
2.4 Exosomes in Biology
2.5
Exosomes in Medicine
2.6 Exosomes as a Therapeutic Target
2.7
Exosomes as Drug Delivery Vehicles
2.8 Therapeutic Preparation of
Exosomes
2.9 Exosomes in Therapeutic Research
2.10 Exosomes in
Oncology
2.11 Exosomes in CNS Disease
2.12 Exosomes in Other
Diseases
3 Assessment of Pipeline Product Innovation
3.1
Overview
3.2 Exosome Pipeline by Stage of Development and Molecule
Type
3.3 Pipeline by Molecular Target
3.4 Pipeline by Therapy
Area and Indication
3.5 Pipeline Product Profiles
3.5.1 AB-126
- ArunA Biomedical Inc.
3.5.2 ALX-029 and ALX-102 - Alxerion Biotech
3.5.3
Biologics for Autism - Stem Cell Medicine Ltd
3.5.4 Biologic for
Breast Cancer - Exovita Biosciences Inc.
3.5.5 Biologics for
Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis -
Regenasome Pty
3.5.6 Biologic for Lysosomal Storage Disorder -
Exerkine
3.5.7 Biologics for Prostate Cancer - Cells for Cells
3.5.8
CAP-2003 - Capricor Therapeutics Inc.
3.5.9 CAP-1002 - Capricor
Therapeutics Inc.
3.5.10 CIL-15001 and CIL-15002 - Ciloa
3.5.11
ExoPr0 - ReNeuron Group Plc
3.5.12 MVAX-001 - MolecuVax Inc.
3.5.13
Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan
University of Medical Sciences
3.5.14 Oligonucleotides to Inhibit
KRAS for Pancreatic Cancer - Codiak BioSciences Inc.
3.5.15
Proteins for Neurology and Proteins for CNS Disorders and
Oligonucleotides for Neurology - Evox Therapeutics Ltd
3.5.16
TVC-201 and TVC-300 - Tavec Inc.
4 Assessment of
Clinical Trial Landscape
4.1 Interventional Clinical Trials
4.1.1
Clinical Trials by Therapy Type
4.1.2 Clinical Trials by Therapy
Area
4.1.3 Clinical Trials by Stage of Development
4.1.4
Clinical Trials by Start Date and Status
4.2 Observational Clinical
Trials
5 Company Analysis and Positioning
5.1
Company Profiles
5.1.1 Capricor Therapeutics Inc.
5.1.2 Evox
Therapeutics Ltd
5.1.3 ReNeuron Group Plc
5.1.4 Stem Cell
Medicine Ltd
5.1.5 Tavec Inc.
5.1.6 Codiak Biosciences Inc.
5.1.7
Therapeutic Solutions International Inc.
5.1.8 ArunA Biomedical Inc.
5.1.9
Ciloa
6 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/gglddw/global_exosome?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181122005347/en/
Editor Details
-
Company:
- Business Wire
- Website: